These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 10680987)

  • 1. Trovafloxacin susceptibility of aerobic clinical bacterial isolates from Sweden.
    Rylander M; Walder M; Lind-Brandberg L; Larsson P; Törnqvist E; Monsen T; Kronvall G
    Scand J Infect Dis; 1999; 31(6):567-72. PubMed ID: 10680987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species.
    Kronvall G; Holst E
    Clin Microbiol Infect; 2000 Apr; 6(4):195-201. PubMed ID: 11168107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of trovafloxacin against ciprofloxacin-susceptible and -resistant clinical bacterial isolates and assessment of the trovafloxacin disk test.
    Fuchs PC; Barry AL; Brown SD
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):33-8. PubMed ID: 9990473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
    Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
    Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin.
    Fuentes F; Giménez MJ; Marco F; Alou L; Aguilar L; Prieto J
    Eur J Clin Microbiol Infect Dis; 2000 Feb; 19(2):137-9. PubMed ID: 10746503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
    Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of trovafloxacin tested against ciprofloxacin-susceptible and -resistant Neisseria gonorrhoeae. Interpretive criteria and comparisons with Etest results.
    Jones RN; Barrett MS; Deguchi T
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):193-200. PubMed ID: 9327248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of recent gram-positive isolates to ciprofloxacin, levofloxacin, and trovafloxacin.
    Isenberg HD; Alperstein P; France K
    Diagn Microbiol Infect Dis; 1998 Oct; 32(2):115-8. PubMed ID: 9823535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calibration of disk diffusion antibiotic susceptibility testing: species-related trovafloxacin interpretive zone breakpoints and selection of disk potency.
    Kronvall G; Rylander M; Walder M; Lind-Brandberg L; Larsson P; Törnqvist E; Monsen T
    Scand J Infect Dis; 1999; 31(6):573-8. PubMed ID: 10680988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
    McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro activity of trovafloxacin in 238 respiratory pathogens].
    Alarcón T; Domingo D; Prieto N; Sánchez S; López-Brea M
    Rev Esp Quimioter; 1998 Mar; 11(1):47-51. PubMed ID: 9795289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates.
    Verbist L; Verhaegen J
    Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):683-5. PubMed ID: 8894581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topoisomerase sequences of coagulase-negative staphylococcal isolates resistant to ciprofloxacin or trovafloxacin.
    Dubin DT; Fitzgibbon JE; Nahvi MD; John JF
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1631-7. PubMed ID: 10390214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
    Ling TK; Liu EY; Cheng AF
    Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.